Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTwP-HepB-Hib vaccine (Sanofi)
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTwP-HepB-Hib vaccine is a pentavalent (5-in-1) combination vaccine that provides immunization against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and Haemophilus influenzae type b. It contains diphtheria toxoid, tetanus toxoid, whole-cell pertussis antigens (wP), hepatitis B surface antigen, and Hib polysaccharide conjugate. The mechanism of action is immunostimulation—each component induces an immune response to its respective pathogen. This vaccine is primarily used in infants and young children as part of routine immunization schedules in many low- and middle-income countries. It has been shown to be safe and effective as a three-dose primary series[1][4][5]. Several formulations have received WHO prequalification or regulatory approval; for example, Quintanrix was approved by the European Medicines Agency in 2004 but later withdrawn[1]. The product is widely procured by UNICEF for global child vaccination programs[3].
- Brand names
- Easyfive-TTQuintanrix
- Other names
- pentavalent vaccine5-in-1 combination vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxin
Beyond the preview
Go deeper on DTwP-HepB-Hib vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTwP-HepB-Hib vaccine (Sanofi).